You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination

Article metrics

Article menu

Download PDFPDF

Letter
Effects of casirivimab/imdevimab on systemic and mucosal immunity against SARS-CoV-2 in B-cell depleted patients with autoimmune rheumatic diseases refractory to vaccination

 

Online download statistics by month:

Online download statistics by month: May 2022 to October 2024

AbstractFullPdf
May 202216116252
Jun 202212912832
Jul 20221069920
Aug 202213813315
Sep 2022908627
Oct 2022757622
Nov 2022404118
Dec 2022323210
Jan 2023666516
Feb 2023494719
Mar 2023333024
Apr 2023252212
May 2023192013
Jun 202319178
Jul 202314137
Aug 202318176
Sep 202310116
Oct 202314136
Nov 202315143
Dec 202319198
Jan 2024282822
Feb 2024191925
Mar 2024262662
Apr 2024212016
May 202423236
Jun 2024272210
Jul 2024181610
Aug 202415168
Sep 2024171710
Oct 202412128
Total12781244501